HCPCS code J9312: Rituximab billing guide for rheumatology and oncology

Key Takeaways

HCPCS code J9312 describes injection, rituximab, 10 mg – each billing unit equals 10 mg, so a 1,000 mg dose requires 100 units

J9312 replaced retired code J9310 effective January 1, 2019. Never use J9310 on current claims

Biosimilar codes Q5115 (Truxima), Q5119 (Ruxience), and Q5123 (Riabni) are billed instead of J9312 when a biosimilar is dispensed

Pabau’s claims management software helps infusion practices track drug units, link ICD-10 codes, and reduce rituximab claim denials

HCPCS code J9312 is the HCPCS Level II code for injection, rituximab, 10 mg, the intravenous monoclonal antibody used across oncology and rheumatology. This guide walks through unit calculations, the CPT codes billed alongside J9312, the ICD-10 diagnoses that support medical necessity, the three rituximab biosimilar codes, Medicare reimbursement under the buy-and-bill model, and drug wastage documentation. Practice management software like Pabau helps infusion practices keep units, diagnoses, and claims connected from one encounter record.

HCPCS code J9312: Definition, unit structure, and clinical description

Rituxan billing and coding comes down to one rule that most claims get wrong: HCPCS code J9312 represents 10 mg of rituximab per unit, not 100 mg and not one vial. Most rituximab claim denials trace back to a unit-calculation error. Pabau’s claims management software handles the math, but the coder still needs to know the increment.

According to the CMS HCPCS system, the official long descriptor for J9312 is “Injection, rituximab, 10 mg.” CMS classifies it under chemotherapy drugs within HCPCS Level II J-codes. The code has been valid and active since January 1, 2019, when it replaced the now-retired J9310.

Rituximab (brand name Rituxan, manufactured by Genentech/Biogen) is a chimeric anti-CD20 monoclonal antibody approved by the FDA for multiple indications spanning oncology and rheumatology. The drug is commercially available in two single-use vial sizes: 100 mg/10 mL and 500 mg/50 mL.

Because the code and the product are tied together, the Rituxan HCPCS code is simply J9312 whenever the reference product is administered.

How to calculate J9312 billing units

Divide the total administered dose (in mg) by 10 to get the number of J9312 units to bill. These examples illustrate the most common dosing scenarios:

Bill only for the dose actually administered. If 750 mg was ordered but 800 mg was drawn to account for tubing priming, the billable units remain 75, not 80. Waste documentation rules (discussed below) govern any separately billable overage.

Coders searching for a CPT code for Rituxan 1000 mg are really looking for J9312: a 1,000 mg dose is billed as 100 units of J9312, because the drug code carries the quantity, not a dose-specific CPT code.

J9312 vs J9310: Transition history and why it matters

Before January 1, 2019, practices billed rituximab under J9310, which was defined as rituximab 100 mg per unit. CMS retired J9310 and introduced HCPCS code J9312 at the 10 mg per unit increment, bringing the code structure in line with other oncology biologics where smaller unit sizes reduce the risk of dose-calculation errors on claims.

Claims submitted with J9310 after December 31, 2018 will deny. Genentech’s J-code announcement confirmed the transition date, and The Rheumatologist’s coding corner articles corroborate it. Any payer edits or billing templates still referencing J9310 require immediate correction.

CPT codes used alongside HCPCS code J9312 for a rituximab infusion visit

J9312 is a drug code only. It identifies the drug administered but does not capture the professional work of infusing it. Coders often search for a CPT code for rituximab or a Rituxan CPT code, but rituximab has no CPT code of its own.

It is reported with the HCPCS drug code J9312, while the CPT codes on the claim describe only the infusion administration. Infusion administration services require separate CPT codes billed on the same claim. For infusion billing best practices, the correct combination depends on infusion duration, not on the drug itself.

A standard rituximab infusion in a physician office or infusion suite follows this CPT structure, based on guidance published by The Rheumatologist:

The Rheumatologist’s published coding example for a 1,000 mg rheumatoid arthritis infusion uses: 96413, 96415 x 3, J9312 x 100, 96375, and J2920 (methylprednisolone). Actual code combinations and units must reflect what is documented in the clinical note, including start and stop times for each infused agent.

Relying on infusion administration CPT codes alone without the J-code will result in a split claim deficiency.

Place-of-service considerations

The CPT codes above apply in the physician office setting (Place of Service 11). In a hospital outpatient department (POS 22), the facility bills the administration codes under its outpatient prospective payment system (OPPS). The physician bills only the professional component, and J9312 may be billed by the hospital separately under its own claim. Verify POS assignment on every rituximab claim before submission.

ICD-10 diagnosis codes required for HCPCS code J9312 claims

Every J9312 claim requires at least one rituximab ICD-10 diagnosis code that supports medical necessity. Medicare and most commercial payers cross-reference the submitted diagnosis against rituximab’s FDA-approved indications. Submitting an unsupported diagnosis code is the second most common reason for J9312 denials, after unit errors.

Applying the same documentation rigor used for a code like D69.3 in other specialties is essential here. Louisiana Medicaid’s HUM-7234 notification restricts J9312 reimbursement to claims carrying specific diagnosis codes, illustrating how state Medicaid programs can narrow coverage beyond federal policy.

The J9312 covered diagnosis list most commonly includes:

• C82-C86 (Non-Hodgkin’s lymphoma subtypes): the original FDA oncology indication
• C91.1 (Chronic lymphocytic leukemia): CLL indication approved in combination with chemotherapy
• M05.xx / M06.xx (Rheumatoid arthritis): RA with positive serology or unspecified RA. Specific 5th/6th character codes should reflect joint involvement and serology status
• M31.30 / M31.31 (Granulomatosis with polyangiitis, GPA): approved for induction and maintenance
• M31.7 (Microscopic polyangiitis, MPA): approved for induction and maintenance
• L10.0 (Pemphigus vulgaris): FDA-approved indication added after original launch
• C91.0 (Acute lymphoblastic leukemia): included in Louisiana Medicaid’s approved diagnosis list

Payer local coverage determinations (LCDs) may include additional or fewer diagnosis codes than this list. Always check the applicable Medicare Administrative Contractor (MAC) LCD and the commercial payer’s rituximab policy before submitting.

The same specificity rule applies across every specialty: code to the highest level of specificity available. The unspecified M31.9 is a good example of what payers reject when a more specific GPA or MPA code is documented instead.

Rituximab biosimilar HCPCS codes: J9312 vs Q5115, Q5119, and Q5123

Three FDA-approved rituximab biosimilars have their own HCPCS codes distinct from J9312. When a biosimilar is dispensed rather than the reference product (Rituxan), the biosimilar’s HCPCS code must be billed, not J9312. Substituting J9312 for a biosimilar code (or vice versa) creates a National Drug Code (NDC) mismatch that triggers a claim edit.

Guidance from the AAPC HCPCS code lookup and Louisiana Medicaid’s HUM-7234 notification confirm all four codes are treated as the same therapeutic class for coverage purposes, but each maps to a distinct product and manufacturer:

All four codes share the 10 mg per unit structure, so the unit calculation method is identical. The distinction is product-specific NDC reporting.

Medicare Part B requires the specific NDC of the drug administered to accompany the HCPCS code on the claim. Biosimilar interchangeability designations with the FDA may evolve. Verify current FDA status before assuming automatic substitutability in your state.

Each biosimilar has its own J-code. The Ruxience J-code is Q5119, the Truxima J-code is Q5115, and Riabni uses Q5123, all billed at the same 10 mg per unit as J9312.

Coders frequently search for a Ruxience CPT code, a Truxima CPT code, or a Q5115 CPT code, but none of these products has a CPT code. Like J9312, each one is a HCPCS drug code, and the Q5119 CPT code description and Q5123 CPT code description that payers publish simply restate the same 10 mg-per-unit HCPCS descriptor.

The CPT codes on a biosimilar claim cover only the infusion administration, exactly as they do for the Rituxan reference product.

The same NDC-to-HCPCS mapping discipline extends to other physician-administered biologics. See Q5123 for the Amgen product’s own billing detail, or Q5104 for how the same rules apply to an infliximab biosimilar.

Streamline rituximab infusion billing with Pabau

Pabau's claims management tools help rheumatology and oncology practices track drug units, link ICD-10 codes, and submit clean J9312 claims the first time. See how it works for infusion practices.

Book a demo

Medicare reimbursement and the buy-and-bill model for J9312

Medicare Part B reimburses physician-administered drugs like J9312 at Average Sales Price (ASP) plus 6%, per CMS’s standard buy-and-bill policy. The ASP is recalculated each calendar quarter based on manufacturer-reported sales data. Because the rate fluctuates, specific dollar figures published outside an official CMS quarterly update should not be treated as current.

The CMS Physician Fee Schedule lookup provides the most current payment rates by code and locality. For J9312, check the applicable quarter’s ASP Drug Pricing File at CMS.gov under Medicare Part B Drug Reimbursement.

Practices in the buy-and-bill model purchase rituximab directly from a distributor, administer it, and then seek reimbursement from the payer. The spread between acquisition cost and ASP+6% reimbursement determines the economic viability of this model for a given practice.

Hospital outpatient departments typically receive OPPS payment rather than ASP+6%. This rate difference is a significant factor for practices deciding whether to administer infusions in-office or refer patients to a hospital infusion center. For IV therapy practice management teams evaluating buy-and-bill economics, tracking acquisition cost alongside reimbursement rate by quarter is essential financial oversight.

Prior authorization requirements

Medicare does not require prior authorization for J9312 in most settings, but commercial payers almost universally do. Authorization requirements typically include:

• FDA-approved indication documentation
• Failure of first-line therapies (step therapy)
• Baseline lab values
• Prescribing physician specialty

Obtain authorization before drug procurement to avoid administering a dose that will not be covered. Authorization numbers should be captured in the patient record and transmitted on the claim where required by the payer.

Drug wastage billing rules for HCPCS code J9312

Rituximab comes in single-use vials. Once opened, any unused portion must be discarded. CMS allows billing for drug wastage when the following conditions are met: the vial was opened for a specific patient, the patient received at least a partial dose, and the wastage is documented in the medical record.

The documentation requirement is the critical factor. Per CMS policy, the record must note:

• The amount administered
• The amount wasted
• A statement that the remainder could not be used for another patient

Applying the same structured documentation mindset used for oncology codes like C77.8 to drug administration records prevents denial of wastage claims for inadequate documentation.

A concrete example: a patient receives 750 mg of rituximab, drawn from a 500 mg vial and a 250 mg portion of a second 500 mg vial. The remaining 250 mg in the second vial is wasted.

The practice bills 75 units of J9312 for the dose administered. It then bills an additional 25 units for the wasted 250 mg, appending modifier JW to the wastage line. The JW modifier signals to the payer that the units on that line represent discarded drug, not additional dose.

Some payers also require modifier JZ on lines where no wastage occurred, confirming that zero drug was wasted from that vial. Verify each payer’s specific modifier requirements before billing. For procedure code billing accuracy across complex multi-drug infusion visits, maintaining a clear separation between administered-dose lines and wastage lines in your billing system avoids edit-triggered denials.

Payer coverage and state Medicaid considerations for J9312

Federal Medicare policy sets the baseline for J9312 coverage, but commercial payers and state Medicaid programs can impose additional restrictions. Understanding these layers is necessary for both infusion EMR software configuration and pre-authorization workflows.

Louisiana Medicaid’s HUM-7234 notification illustrates the state-level variation: it explicitly restricts J9312 and its biosimilar codes (Q5115, Q5119, Q5123) to claims submitted with an approved diagnosis list that includes acute lymphoblastic leukemia, Non-Hodgkin’s lymphoma subtypes, CLL, RA, GPA, MPA, and pemphigus vulgaris.

Diagnoses outside this list will deny regardless of clinical appropriateness. Louisiana’s subsequent HUM-7501 notification updated related biosimilar coverage requirements.

Key payer variables to verify for every J9312 patient:

• Step therapy requirements: most commercial plans require documented failure of conventional DMARDs before approving rituximab for RA
• Approved diagnosis codes: check the payer’s specific rituximab policy, not just the general coverage list
• Specialty restrictions: some payers limit rituximab authorization to rheumatologists or oncologists only
• Infusion setting requirements: certain payers require hospital outpatient infusion rather than physician office administration
• Biosimilar mandates: payers increasingly require biosimilar trial before authorizing the reference product (Rituxan)

Maintaining HIPAA-compliant clinical documentation throughout the authorization and infusion process is a baseline requirement. The documentation trail from prior authorization through administered dose to billing is what supports the claim in an audit.

How Pabau supports rituximab infusion billing workflows

Rituximab billing involves more moving parts than most infusion codes: multi-unit drug calculations, paired administration CPT codes, mandatory NDC reporting, wastage modifier logic, and payer-specific prior authorization. Each step creates a potential error point.

Pabau’s claims management software is designed for multi-specialty clinical practices running complex billing workflows. The platform supports drug code documentation, ICD-10 code linkage at the encounter level, and structured treatment records that capture the clinical detail payers require at audit.

For practices building out prescription management software workflows for buy-and-bill drugs, Pabau connects the clinical record to the billing output so unit calculations and diagnosis linkages carry forward from the documented encounter rather than being re-entered manually downstream.

Practices managing infusion patients alongside other patient populations can also use Pabau’s intake and consent forms to collect structured pre-infusion screening data, medication history, and consent documentation in a format that integrates directly with the patient record.

Conclusion

HCPCS code J9312 is a technically precise code: 10 mg per unit, active since January 2019, requiring paired infusion CPT codes, a valid ICD-10 diagnosis, and correct biosimilar code selection when applicable. Any of the following can stop a claim independently:

• Getting the unit count wrong
• Using the retired J9310
• Failing to document wastage properly
• Submitting an unsupported diagnosis code

Pabau’s claims management software helps infusion practices structure the encounter documentation that supports clean J9312 claims. To see how it handles complex drug billing workflows, book a demo with the Pabau team.

Continue your research

Need to cross-reference ICD-10 codes for rheumatology patients? ICD-10 diagnosis code documentation covers specificity rules that apply across specialty billing workflows.

Running a multi-service infusion practice? Infusion billing best practices covers operational and compliance considerations for infusion-focused practices.

Evaluating EMR software for your infusion practice? Best IV therapy EMR reviews features specific to infusion and IV therapy practice management.

Coding a different procedure this week? Catheter drainage billing breaks down HCPCS code C1729 for drainage catheter supplies.

Billing physical medicine services alongside infusion care? Massage therapy billing covers CPT code 97124 for practices that offer manual therapy.

Frequently asked questions